MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
41.06
+0.04
+0.10%
After Hours: 41.06 0 0.00% 16:20 05/12 EDT
OPEN
41.04
PREV CLOSE
41.02
HIGH
41.08
LOW
41.03
VOLUME
6.34M
TURNOVER
--
52 WEEK HIGH
41.14
52 WEEK LOW
16.10
MARKET CAP
5.26B
P/E (TTM)
41.04
1D
5D
1M
3M
1Y
5Y
1D
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 9h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)
TipRanks · 1d ago
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanks · 1d ago
Weekly Report: what happened at APLS last week (0504-0508)?
Weekly Report · 1d ago
Is It Too Late To Consider Apellis Pharmaceuticals (APLS) After Its 130% One Year Surge?
Simply Wall St · 3d ago
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
Benzinga · 4d ago
Apellis Pharmaceuticals (APLS) Q1 Profitability Reinforces Bullish Earnings Quality Narrative
Simply Wall St · 5d ago
Remitly Global to replace Apellis in S&P 600 at open on 5/14
TipRanks · 5d ago
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.